August 2020 - Global Life Science Business Partnering - News & Updates

Highlights of August 2020

  1. Beximco Pharma announced investment in Serum Institute of India (SII) for priority access to COVID-19 vaccines being developed by the Indian pharma manufacturer.
  2. Wockhardt, India has announced that it has entered into an agreement with the UK Government to fill-finish COVID-19 vaccines.
  3. Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership.
  4. Biological E inks licensing agreement with BCM for COVID-19 vaccine.
  5. J&J ties up with Biological E for manufacturing Covid vaccine in India.
  6. Lupin, ForDoz Pharma Ink Deal For Development Of 2 Complex Injectable Products.
  7. Piramal Pharma partners with Epirium Bio on orphan drugs development.
  8. Bristol Myers Squibb pens US$475 Million Dragonfly pact for IL-12 program.
  9. Bayer inks US$425 Million upfront KaNDy buyout to challenge Astellas for menopause market.
  10. Bio-Thera Solutions and BeiGene Announce License, Distribution, and Supply Agreement for Avastin® (Bevacizumab) Biosimilar BAT1706 in China for up to US$165 Million.
  11. Medivir and SciLifeLab collaborate on potential SARS CoV-2 inhibitors.
  12. Redx out-licenses fibrotic asset to AstraZeneca.
  13. Investment firm GI Partners snaps up Clinical Ink amid digital trial boom.
  14. Medtronic snaps up smart insulin pen maker Companion Medical in a 'bold move'.

Highlights at Aagami

  • Major Step: Aagami’s Australian Biotech client successfully completed a term sheet with a large global Pharma company from India
  • New Client Win: US Pharma selects Aagami for divesting 2 oncology assets.
    • Patented Albumin-Stabilized PEGylated Liposomal Docetaxel
    • Complex Generic PEGylated Liposomal Doxorubicin
  • Aagami to attend (Digitally):
    • BioPharm America™ (September 21–24, 2020)
    • BIO-Europe® (October 26–29, 2020)

    Some of the partnering opportunities available at Aagami are:

    For Acquisition:

    1. Mountain View Pharma (MVP) and its PharmaPEG® technology open for acquisition  Opportunities for:

    • Creation of novel “BioBetters” to differentiate within the fast-growing biosimilars market
    • Product life-cycle management with new intellectual property to extend market protection
    • Company Acquisition would include:
      • Novel patent portfolio
      • Data packages for >22 proteins, peptides and other therapeutics
      • U.S. and California NOL carry-forwards available for income-generating companies (Direct benefit of up to US$ 8.8 Million)

    2. Patented Docetaxel and Complex Generic Doxorubicin

    • Patented - Albumin-Stabilized PEGylated Liposomal Docetaxel
    • Complex Generic - PEGylated Liposomal Doxorubicin

    For Investment with our clients:

    1. Seeking up to US$10M in Current Tranche of Series B for US Innovator bringing Confluence of Portable MRI, Robotics & AI in a Physician's Office. The company has already raised the first tranche (May 15th, 2020) of Series B1 funding ($15M+). The client is now in the process of doing a second close on the Series B-1 round in August and have commitments from several existing investors and new investors, such as Philip Dolan, Kineticos, and MicroPort.
    2. Seeking up to $5M bridge to Series B at $16M cap for a magnetic drug device platform that delivers minimally invasive and targeted treatment for hard to reach targets. Use of proceeds: IND submission, Phase 1 study. Raised over $10M in non-dilutive grants & NIH contracts. Closed $2.33M in Series A
    3. Seeking US$1.5M for Drug-device to delay the progression of Parkinson’s disease (PD), prevent Asian Flush and Hangover.
    4. Seeking US$1M for expansion of an Oncology focused healthcare and data science

    For Licensing/Partnering/Co-development:

    1. Selection Technology using Bacteriocin-Immunity for Improved Microbial (E. coli.) Fermentation.
    2. On the Market Pro-immunity anti-cancer capsules of Rapid and synchronized dormancy-broken Kyoho grape seed endosperm from our Japanese client.

      ×
      Twitter